Glass Lewis backs two of Deep Track's four nominees in Dynavax fight > 독자투고

본문 바로가기
사이트 내 전체검색


기사제보

광고상담문의

(054)256-0045

평일 AM 09:00~PM 20:00

토요일 AM 09:00~PM 18:00

독자투고
Home > 기사제보 > 독자투고

Glass Lewis backs two of Deep Track's four nominees in Dynavax fight

페이지 정보

작성자 AH 작성일25-09-24 13:19 (수정:25-09-24 13:19)

본문

연락처 : AH 이메일 : leonelcalderone@yahoo.ca

By Svea Herbst-Bayliss

NEW YORK, June 4 (Reuters) - Buy Fast Proxy advisory firm Glass Lewis urged Dynavax Technologies shareholders to elect two of investment firm Deep Track Capital's four director nominees, arguing change is needed because the company has not been responsive enough to shareholders.

Glass Lewis recommended in a report that shareholders vote for Brett Erkman, a Deep Track managing director, and biotech industry executive Donald Santel to replace sitting directors Brent MacGregor and Scott Myers, the current board chair.

Emeryville, California-based Dynavax, which makes a vaccine designed to prevent the hepatitis B infection that can lead to chronic liver disease and death, has an 11-member board but only four are standing for election this year.photo-1565065789724-93e2d960b981?ixid=M3wxMjA3fDB8MXxzZWFyY2h8OHx8Y2hlYXBlc3QlMjBwcm94aWVzfGVufDB8fHx8MTc1ODY4NzU1NHww\u0026ixlib=rb-4.1.0

Shareholders will cast ballots at the June 11 annual meeting unless the two sides reach a settlement beforehand. Proxy advisory firm recommendations often guide how money managers vote on hot button issues like corporate elections and mergers.

"Shareholders should support the change of two incumbent board seats given the company's prolonged capital conservatism and the board's limited responsiveness to shareholder feedback," the report said. The two Deep Track nominees would bring "relevant and differentiated experience to the board," it added.

Erkman has worked as a private equity investor in life sciences and Santel is a life sciences executive who has done deals.

Deep Track, Dynavax's second largest shareholder with a nearly 15% stake, wants new directors to prioritize development of the company's hepatitis B vaccine Heplisav instead of pursuing new acquisitions. Dynavax is valued at $1.2 billion and its share price has dropped 22% this year.

In May, Institutional Shareholder Services, Glass Lewis' bigger rival, recommended that all company directors be reelected, arguing Deep Track failed to make its case for change.

A Deep Track representative welcomed the report. Dynavax disagreed with the recommendation, saying Glass Lewis noted its board "has been meaningfully refreshed with high quality and sector-specific expertise," a company representative said. (Reporting by Svea Herbst-Bayliss; Editing by Richard Chang)

댓글목록

등록된 댓글이 없습니다.


회사소개 광고문의 기사제보 독자투고 개인정보취급방침 서비스이용약관 이메일무단수집거부 청소년 보호정책 저작권 보호정책

법인명 : 주식회사 데일리광장 | 대표자 : 나종운 | 발행인/편집인 : 나종운 | 사업자등록번호 : 480-86-03304 | 인터넷신문 등록번호 : 경북, 아00826
등록일 : 2025년 3월 18일 | 발행일 : 2025년 3월 18일 | TEL: (054)256-0045 | FAX: (054)256-0045 | 본사 : 경북 포항시 남구 송림로4

Copyright © 데일리광장. All rights reserved.